Join STAT’s senior science writer, Sharon Begley, for an online chat about the latest developments with the genome-editing technology CRISPR. She’ll take your questions about two new studies raising concerns about whether CRISPR’d cells might become cancerous, about the CRISPR patent wars, and about the ongoing science summarized in STAT’s CRISPR Trackr.

Read the chat archive below

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy